Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy-Reference-Cited by-同舟云学术

Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy

Published:2022-10-07 Issue:11 Volume:8 Page:4819-4826
ISSN:2373-9878
Container-title:ACS Biomaterials Science & Engineering
language:en
Short-container-title:ACS Biomater. Sci. Eng.

Author:

Xu Xichao¹,Liu Liang¹,Wang Huan¹,Li Wenwen¹,Zou Yigui¹,Zeng Yinzhen¹,Yang Qinghua¹,Bai Daming¹,Dai Dongling¹^ORCID

Affiliation:

1. Key Laboratory for Precision Diagnosis and Treatment of Pediatric Digestive System Diseases, Endoscopy Center and Gastroenterology Department, Shenzhen Children’s Hospital, Shenzhen 518036, China

Funder

Shenzhen Innovation and Technology Committee

Publisher

American Chemical Society (ACS)

Subject

Biomedical Engineering,Biomaterials

Link

https://pubs.acs.org/doi/pdf/10.1021/acsbiomaterials.2c00639

Reference43 articles.

1. Global cancer statistics, 2012

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Hepatocellular carcinoma

4. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies

5. Improving cancer immunotherapy through nanotechnology

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A metal-organic framework (MOF) built on surface-modified Cu nanoparticles eliminates tumors via multiple cascading synergistic therapeutic effects;Journal of Colloid and Interface Science;2024-05

2. Targeted delivery of T-cell agonists for enhancing immunotherapy;Journal of Drug Delivery Science and Technology;2023-11